Recombinant Human DOCK7 Protein: Functions & Research Applications

Recombinant Human DOCK7 Protein is a biologically active guanine nucleotide exchange factor (GEF) that activates Rho-family GTPases, notably Rac1 and Cdc42, playing pivotal roles in neuronal polarity establishment, axon formation, and directed cell migration.

Protein Name

Recombinant Human DOCK7 Protein

SKU

rp374909

Protein Family

DOCK180 superfamily (DOCK-C subfamily)

Primary Function

Guanine nucleotide exchange factor (GEF) for Rac1 and Cdc42

Key Domains

DHR1 (Docker Homology Region 1) and DHR2 (catalytic GEF domain)

Research Areas

Neurobiology, cytoskeletal dynamics, cell polarity, cancer cell invasion

Species Origin

Human (Homo sapiens)

What Is DOCK7? Biology and Molecular Background

DOCK7 (Dedicator of Cytokinesis 7) is a member of the DOCK180 superfamily of atypical guanine nucleotide exchange factors (GEFs). Unlike classical Dbl-family GEFs, DOCK proteins lack canonical DH-PH domains and instead utilize a unique catalytic module known as the DHR2 (DOCK Homology Region 2) domain to facilitate GDP-to-GTP exchange on Rho-family GTPases. DOCK7 belongs to the DOCK-C (also called DOCK6–8) subfamily and preferentially activates Rac1 and Cdc42, two small GTPases that govern actin cytoskeleton remodeling, cell polarity, and membrane protrusion dynamics.

DOCK7 is encoded by the DOCK7 gene located on human chromosome 1p31.3. The protein contains an N-terminal SH3 domain, a DHR1 domain that binds phosphoinositides for membrane targeting, and a C-terminal DHR2 domain that constitutes the catalytic GEF activity. Together, these structural elements ensure precise spatiotemporal control of Rho GTPase activation in response to upstream signals.

Emerging evidence has implicated DOCK7 in a range of physiological and pathological processes, including neuronal morphogenesis, Schwann cell myelination, and tumor cell invasiveness, making it a compelling target for mechanistic cell biology studies.

Role of DOCK7 in Neuronal Polarity and Axon Formation

One of the best-characterized functions of DOCK7 is its essential role in establishing neuronal polarity. During cortical neuron development, neurons must specify a single axon from multiple undifferentiated neurites — a process that requires asymmetric activation of Rac1 and Cdc42. DOCK7 localizes to the nascent axon tip, where its GEF activity locally activates Rac1 and Cdc42, driving actin polymerization and microtubule stabilization necessary for axon elongation.

Studies in cultured hippocampal neurons have demonstrated that overexpression of DOCK7 promotes supernumerary axon formation, while loss-of-function approaches suppress axon specification. These effects are mediated through downstream effectors including PAK kinases and LIMK, which regulate cofilin-dependent actin dynamics. DOCK7 has also been shown to interact with the Par3/Par6/aPKC polarity complex, integrating extracellular cues with internal cytoskeletal reorganization.

Given this mechanistic insight, Recombinant Human DOCK7 Protein provides a valuable tool for in vitro reconstitution assays aimed at dissecting the biochemical steps of GEF-catalyzed Rac1 and Cdc42 activation during neuronal differentiation.

Research Applications of Recombinant Human DOCK7 Protein

Recombinant Human DOCK7 Protein (SKU: rp374909) is designed to support a broad spectrum of biochemical and cell biological research applications:

• GEF Activity Assays: The recombinant protein can be used in mant-GDP–based fluorescence exchange assays or radioactive GTP-loading assays to quantify its intrinsic nucleotide exchange activity toward Rac1 and Cdc42 substrates.
• Protein–Protein Interaction Studies: DOCK7 serves as a bait or prey protein in pull-down and co-immunoprecipitation experiments to identify novel binding partners in signaling networks.
• Structural Biology: Purified recombinant DOCK7 provides a homogeneous protein preparation suitable for X-ray crystallography, cryo-EM studies, or SAXS analyses aimed at resolving DHR1/DHR2 domain conformations.
• Drug Discovery and Screening: DOCK7 is a candidate target in oncology; recombinant protein enables high-throughput screening of small-molecule inhibitors that block GEF–GTPase interactions.
• Western Blot and ELISA Standards: The recombinant protein serves as a positive control or quantitative standard in immunodetection assays.
• Cell-Free Reconstitution: DOCK7 can be incorporated into reconstituted cytoskeletal dynamics systems to study actin branching and polarity establishment in a defined biochemical context.

Researchers should consult the product datasheet for recommended storage conditions, buffer composition, and validated assay formats prior to experimental use.

DOCK7 in Disease and Translational Relevance

Beyond its role in normal cell biology, DOCK7 has been implicated in several human diseases, heightening its translational significance:

Epilepsy and Neurodevelopmental Disorders: Biallelic loss-of-function mutations in DOCK7 have been identified in patients with severe intellectual disability and intractable epilepsy, underscoring the non-redundant role of this GEF in human brain development. These findings motivate the use of recombinant DOCK7 in studying mutant protein function and potential rescue strategies.

Cancer: DOCK7 expression has been reported to be dysregulated in multiple cancer types. In breast cancer and glioblastoma models, elevated DOCK7 activity has been associated with enhanced cell motility and invasiveness, consistent with its role in Rac1/Cdc42-driven lamellipodia and filopodia formation. Recombinant DOCK7 protein facilitates mechanistic studies and supports the identification of inhibitory compounds.

Schwann Cell Biology: DOCK7 regulates Schwann cell morphology and myelination in the peripheral nervous system through Rac1 activation, presenting potential relevance to demyelinating diseases.

These disease associations make Recombinant Human DOCK7 Protein a strategically important reagent for both basic mechanistic research and early-stage translational investigations.

Handling, Storage, and Quality Considerations

To maintain the activity and integrity of Recombinant Human DOCK7 Protein (rp374909), researchers should adhere to the following general best practices (always verify against the official product datasheet):

• Storage: Recombinant proteins are typically stored at –80 °C for long-term preservation. Repeated freeze-thaw cycles should be minimized by preparing single-use aliquots upon first thaw.
• Buffer Compatibility: Ensure the supplied storage buffer is compatible with downstream assay conditions. If buffer exchange is required, use low-protein-binding membranes or desalting columns.
• Carrier Protein: Some formulations include BSA or glycerol as stabilizers; confirm compatibility with your assay format, particularly for activity-based assays where BSA may interfere.
• Quality Control: Aladdin Scientific's recombinant proteins undergo SDS-PAGE purity assessment and, where applicable, functional activity verification. Refer to the Certificate of Analysis (CoA) for lot-specific data.
• Handling: Work on ice when setting up assays. Avoid vortexing; mix gently by pipetting. Centrifuge briefly before opening to collect protein at the tube bottom.

For technical support or custom formulation requests, contact Aladdin Scientific's technical services team directly.

Frequently asked questions

What GTPases does DOCK7 activate, and how does it compare to classical GEFs?

DOCK7 primarily activates Rac1 and Cdc42 through its DHR2 catalytic domain, promoting GDP-to-GTP exchange. Unlike classical Dbl-family GEFs that use a DH-PH domain module, DOCK7 employs a structurally distinct DHR2 domain to engage the GTPase switch regions, making it part of the atypical DOCK180 superfamily.

What assays are validated for use with Recombinant Human DOCK7 Protein?

Recombinant Human DOCK7 Protein is suitable for nucleotide exchange activity assays (e.g., mant-GDP fluorescence assays), pull-down and co-immunoprecipitation studies, Western blot as a positive control standard, and structural biology applications such as crystallography and cryo-EM. Always consult the product datasheet and CoA for lot-specific validated applications.

How should Recombinant Human DOCK7 Protein be stored to preserve activity?

The protein should be stored at –80 °C for long-term use. To avoid repeated freeze-thaw cycles that can denature the protein and reduce GEF activity, prepare small single-use aliquots after the initial thaw. Keep samples on ice during experimental setup and avoid vortexing.

Is DOCK7 relevant to cancer research?

Yes. DOCK7 has been reported to be upregulated in certain cancer types, including breast cancer and glioblastoma, where it promotes Rac1/Cdc42-dependent cell motility and invasion. Recombinant Human DOCK7 Protein can be used in mechanistic oncology studies and as a tool protein for inhibitor screening campaigns targeting DOCK7–GTPase interactions.

What is the chromosomal location of the human DOCK7 gene and are there known disease-associated mutations?

The human DOCK7 gene is located on chromosome 1p31.3. Biallelic loss-of-function mutations in DOCK7 have been identified in patients with severe intellectual disability and intractable epilepsy, highlighting its critical non-redundant role in neurodevelopment. These findings underscore the importance of studying DOCK7 protein function using well-characterized recombinant tools.

References

1. Watabe-Uchida M, et al. The Rac activator DOCK7 regulates neuronal polarity through local assembly of F-actin. J Neurosci. 2006.
2. Yamauchi J, et al. DOCK7 interacts with ErbB2 and is required for Schwann cell myelination. Nat Neurosci. 2008.
3. Jacoby E, et al. Homozygous DOCK7 mutation causes a severe form of epileptic encephalopathy with intellectual disability. Hum Mutat. 2016.
4. Laurin M, Cote JF. Insights into the biological functions of Dock family guanine nucleotide exchange factors. Genes Dev. 2014.

Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.